title: In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
abstract: Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.
authors.affiliation: Institute of Microbiology, University of Ancona Medical School, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Biavasco
authors.forename: E
authors.initials: E
authors.lastname: Manso
authors.forename: P E
authors.initials: PE
authors.lastname: Varaldo
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology; D012310:Ristocetin / Q000031:analogs & derivatives; D017334:Teicoplanin / Q000031:analogs & derivatives; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D006020:Glycopeptides; D010456:Peptides, Cyclic; C041438:ramoplanin; C068029:MDL 62873; D012310:Ristocetin; D017334:Teicoplanin; D014640:Vancomycin; C063101:teicoplanin aglycone